Amiloride: Difference between revisions
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
|drugClass= | |drugClass= | ||
[[potassium-sparing diuretic]] | |||
|indication= | |indication= | ||
Revision as of 19:11, 29 June 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gerald Chi
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
|
See full prescribing information for complete Boxed Warning.
Like other potassium-conserving agents, amiloride may cause hyperkalemia (serum potassium levels greater than 5.5 mEq per liter) which, if uncorrected, is potentially fatal. Hyperkalemia occurs commonly (about 10%) when amiloride is used without a kaliuretic diuretic. This incidence is greater in patients with renal impairment, diabetes mellitus (with or without recognized renal insufficiency), and in the elderly. When MIDAMOR is used concomitantly with a thiazide diuretic in patients without these complications, the risk of hyperkalemia is reduced to about 1-2 percent. It is thus essential to monitor serum potassium levels carefully in any patient receiving amiloride, particularly when it is first introduced, at the time of diuretic dosage adjustments, and during any illness that could affect renal function.
|
Overview
Amiloride is a potassium-sparing diuretic that is FDA approved for the {{{indicationType}}} of . There is a Black Box Warning for this drug as shown here. Common adverse reactions include .
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Condition1
- Dosing Information
- Dosage
Condition2
- Dosing Information
- Dosage
Condition3
- Dosing Information
- Dosage
Condition4
- Dosing Information
- Dosage
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
Condition1
- Developed by:
- Class of Recommendation:
- Strength of Evidence:
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Amiloride in adult patients.
Non–Guideline-Supported Use
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Amiloride in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding FDA-Labeled Use of Amiloride in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
Condition1
- Developed by:
- Class of Recommendation:
- Strength of Evidence:
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Amiloride in pediatric patients.
Non–Guideline-Supported Use
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Amiloride in pediatric patients.
Contraindications
- Condition1
Warnings
|
See full prescribing information for complete Boxed Warning.
Like other potassium-conserving agents, amiloride may cause hyperkalemia (serum potassium levels greater than 5.5 mEq per liter) which, if uncorrected, is potentially fatal. Hyperkalemia occurs commonly (about 10%) when amiloride is used without a kaliuretic diuretic. This incidence is greater in patients with renal impairment, diabetes mellitus (with or without recognized renal insufficiency), and in the elderly. When MIDAMOR is used concomitantly with a thiazide diuretic in patients without these complications, the risk of hyperkalemia is reduced to about 1-2 percent. It is thus essential to monitor serum potassium levels carefully in any patient receiving amiloride, particularly when it is first introduced, at the time of diuretic dosage adjustments, and during any illness that could affect renal function.
|
Description
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Amiloride in the drug label.
Central Nervous System
Cardiovascular
Respiratory
Gastrointestinal
Hypersensitivity
Miscellaneous
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Amiloride in the drug label.
Central Nervous System
Cardiovascular
Respiratory
Gastrointestinal
Hypersensitivity
Miscellaneous
Drug Interactions
- Drug
- Description
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Amiloride in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Amiloride in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Amiloride during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Amiloride with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of Amiloride with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Amiloride with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Amiloride with respect to specific gender populations.
Race
There is no FDA guidance on the use of Amiloride with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Amiloride in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Amiloride in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Amiloride in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Amiloride in patients who are immunocompromised.
Administration and Monitoring
Administration
Oral
Intravenous
Monitoring
Condition1
Description
IV Compatibility
There is limited information regarding IV Compatibility of Amiloride in the drug label.
Overdosage
Acute Overdose
Signs and Symptoms
Description
Management
Description
Chronic Overdose
There is limited information regarding Chronic Overdose of Amiloride in the drug label.
Pharmacology
There is limited information regarding Amiloride Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Amiloride Mechanism of Action in the drug label.
Structure
There is limited information regarding Structure of Amiloride in the drug label.
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Amiloride in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Amiloride in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Amiloride in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Amiloride in the drug label.
Condition1
Description
How Supplied
There is limited information regarding Amiloride How Supplied in the drug label.
Storage
There is limited information regarding Amiloride Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Amiloride |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Amiloride |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Amiloride Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Amiloride interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
Midamor®
Look-Alike Drug Names
- aMILoride — amLODIPine[1]
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
- ↑ "http://www.ismp.org". External link in
|title=(help)